+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Zika Virus Therapeutics Market 2019-2023 - Product Image

Global Zika Virus Therapeutics Market 2019-2023

  • ID: 4790977
  • Report
  • June 2019
  • Region: Global
  • 131 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Aurobindo Pharma Ltd.
  • Perrigo Co. Plc
  • MORE
Global Zika Virus Therapeutics Market: About this market

The Zika virus therapeutics market analysis considers the revenues based on products such as acetaminophen and other nonsteroidal anti-inflammatory drugs (NSAIDs). Our analysis also considers the sales of Zika virus therapeutics in North America, Asia, Europe, and ROW. In 2018, the acetaminophen segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as safety and efficacy will play a significant role in the acetaminophen segment to maintain its market position. , our global Zika virus therapeutics market report looks at factors such as the availability of serology kit for qualitative diagnosis of Zika virus infection, the high incidence rate of infection, and disease burden of Zika virus infection and associated comorbidities. However, the asymptomatic nature of the infection, lack of approved Zika virus therapeutics, and stringent regulatory guidelines may hamper the growth of the Zika virus therapeutics industry over the forecast period.

Global Zika virus therapeutics market: Overview

Rising disease burden of Zika virus infection and associated comorbidities

The incidences of Zika virus infection has been increasing at a significant rate over the last few years and is gradually reaching epidemic proportions across the globe. Zika virus infection can affect both fetuses and adults in the form of various clinical manifestations such as conjunctivitis, maculopapular pruritic rashes, arthralgia, congenital glaucoma, microcephaly, and optic neuropathy. Thus, the rising disease burden of Zika virus infection and associated comorbidities will fuel the expansion of the Zika virus therapeutics market at a CAGR of over 4% during the forecast period.

Novel approach for vaccine development

The Zika virus therapeutics market is witnessing the emergence of novel approaches for vaccine development. The use of ribonucleic acid as a vaccine is one of the novel approaches that have emerged in the market. The promising results of vaccines are further encouraging research organizations to invest in the R&D of the vaccines for human models. Thus, the emergence of novel approaches for vaccine development will fuel the growth of the market during the forecast period.

Competitive Landscape

With the presence of several major players, the global Zika virus therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Zika virus therapeutics companies, that include Aurobindo Pharma Ltd., Johnson & Johnson Services Inc., Perrigo Co. Plc, Sun Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd.

Also, the Zika virus therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aurobindo Pharma Ltd.
  • Perrigo Co. Plc
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: PIPELINE ANALYSIS

PART 07: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Acetaminophen - Market size and forecast 2018-2023
  • Other NSAIDs - Market size and forecast 2018-2023
  • Market opportunity by product
PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • ROW - Market size and forecast 2018-2023
  • North America - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS
  • Increasing efforts by government and private organizations to facilitate vaccine development
  • Classification of Zika virus infection as public health emergency
  • Novel approach for vaccine development
PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Aurobindo Pharma Ltd.
  • Johnson & Johnson Services Inc.
  • Perrigo Co. Plc
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Co. Ltd.
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
PART 16: About the Author


List Of Exhibits
Exhibit 01: Global infectious disease treatment market
Exhibit 02: Segments of global infectious disease treatment market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Some therapeutics in clinical trials for Zika virus infection
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Acetaminophen - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Acetaminophen - Year-over-year growth 2019-2023 (%)
Exhibit 22: Other NSAIDs - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Other NSAIDs - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in ROW
Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in North America
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in Europe
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Aurobindo Pharma Ltd. - Vendor overview
Exhibit 49: Aurobindo Pharma Ltd. - Business segments
Exhibit 50: Aurobindo Pharma Ltd. - Organizational developments
Exhibit 51: Aurobindo Pharma Ltd. - Geographic focus
Exhibit 52: Aurobindo Pharma Ltd. - Key offerings
Exhibit 53: Aurobindo Pharma Ltd. - Key customers
Exhibit 54: Johnson & Johnson Services, Inc. - Vendor overview
Exhibit 55: Johnson & Johnson Services, Inc. - Business segments
Exhibit 56: Johnson & Johnson Services, Inc. - Organizational developments
Exhibit 57: Johnson & Johnson Services, Inc. - Geographic focus
Exhibit 58: Johnson & Johnson Services, Inc. - Segment focus
Exhibit 59: Johnson & Johnson Services, Inc. - Key offerings
Exhibit 60: Johnson & Johnson Services, Inc. - Key customers
Exhibit 61: Perrigo Co. Plc - Vendor overview
Exhibit 62: Perrigo Co. Plc - Business segments
Exhibit 63: Perrigo Co. Plc - Organizational developments
Exhibit 64: Perrigo Co. Plc - Geographic focus
Exhibit 65: Perrigo Co. Plc - Segment focus
Exhibit 66: Perrigo Co. Plc - Key offerings
Exhibit 67: Perrigo Co. Plc - Key customers
Exhibit 68: Sun Pharmaceutical Industries Ltd. - Vendor overview
Exhibit 69: Sun Pharmaceutical Industries Ltd. - Business segments
Exhibit 70: Sun Pharmaceutical Industries Ltd. - Organizational developments
Exhibit 71: Sun Pharmaceutical Industries Ltd. - Geographic focus
Exhibit 72: Sun Pharmaceutical Industries Ltd. - Segment focus
Exhibit 73: Sun Pharmaceutical Industries Ltd. - Key offerings
Exhibit 74: Sun Pharmaceutical Industries Ltd. - Key customers
Exhibit 75: Takeda Pharmaceutical Co. Ltd. - Vendor overview
Exhibit 76: Takeda Pharmaceutical Co. Ltd. - Business segments
Exhibit 77: Takeda Pharmaceutical Co. Ltd. - Organizational developments
Exhibit 78: Takeda Pharmaceutical Co. Ltd. - Geographic focus
Exhibit 79: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibit 80: Takeda Pharmaceutical Co. Ltd. - Key customers
Exhibit 81: Validation techniques employed for market sizing
Exhibit 82: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Aurobindo Pharma Ltd.
  • Perrigo Co. Plc
  • MORE
The following companies are recognised as the key players in the global Zika virus therapeutics market: Aurobindo Pharma Ltd., Johnson & Johnson Services Inc., Perrigo Co. Plc, Sun Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the novel approach for vaccine development.”

According to the report, one of the major drivers for this market is the rising disease burden of Zika virus infection and associated comorbidities.

Further, the report states that one of the major factors hindering the growth of this market is the lack of approved Zika virus therapeutics.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Aurobindo Pharma Ltd.
  • Johnson & Johnson Services Inc.
  • Perrigo Co. Plc
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Co. Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll